InflaRx NV (FRA:IF0)
€ 1.35 0 (0%) Market Cap: 85.25 Mil Enterprise Value: 2.44 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 32/100

Inflarx NV at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 10, 2021 / 02:40PM GMT
Release Date Price: €4.15 (+3.75%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Alright. Welcome, everyone, to the 30th Annual Healthcare Conference of Credit Suisse. I'm Tiago Fauth. I'm biotech analyst here at Credit Suisse and we're joined today by the InflaRx for a fireside chat. Feel free to e-mail me any questions that you might have, and I'll try to work those in, but we can probably get started. As usual, we start with an introduction, kind of key highlights of 2021, where the company is, and then we can dive into some more detailed questions but I don't know, Niels, if you want to just take it away and give a brief overview and all that has changed with InflaRx in the last year or so.

Niels C. Riedemann
InflaRx N.V. - Co-Founder, CEO & Executive Director

Absolutely. First of all, Jake, thanks so much for inviting us to your conference. We are very happy to be here and speak about InflaRx today. I have with me Thomas Taapken, our CFO; and Jordan Zwick, our Chief Strategy Officer. The question was, let's go into what happened

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot